Suppr超能文献

患有内含子 22 基因突变的血友病 A 患者对 FVIII 中的多个表位具有 CD4 T 效应器反应。

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4 T-effector responses to multiple epitopes in FVIII.

机构信息

Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Henry Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States.

出版信息

Front Immunol. 2023 Mar 1;14:1128641. doi: 10.3389/fimmu.2023.1128641. eCollection 2023.

Abstract

BACKGROUND

Almost half of severe hemophilia A (HA) is caused by an intron 22 inversion mutation (Int22Inv), which disrupts the 26-exon gene. Inverted mRNA exons 1-22 are transcribed, while mRNA, containing exons 23-26, is transcribed from a promoter within intron 22. Neither FVIII activity nor FVIII antigen (cross-reacting material, CRM) are detectable in plasma of patients with an intron-22 inversion.

OBJECTIVES

To test the hypothesis that (putative) intracellular synthesis of FVIII proteins encoded by inverted and mRNAs confers T-cell tolerance to almost the entire FVIII sequence, and to evaluate the immunogenicity of the region encoded by the exon 22-23 junction sequence.

PATIENTS/METHODS: Peripheral blood mononuclear cells (PBMCs) from 30 severe or moderate HA subjects (17 with an Int22Inv mutation) were tested by ELISPOT assays to detect cytokine secretion in response to FVIII proteins and peptides and to map immunodominant T-cell epitopes. Potential immunogenicity of FVIII sequences encoded by the exon 22-23 junction region was also tested using peptide-MHCII binding assays.

RESULTS

Eight of the Int22Inv subjects showed robust cytokine secretion from PBMCs stimulated with FVIII proteins and/or peptides, consistent with earlier publications from the Conti-Fine group. Peptide ELISPOT assays identified immunogenic regions of FVIII. Specificity for sequences encoded within mRNA exons 1-22 and mRNA was confirmed by staining Int22Inv CD4 T cells with peptide-loaded HLA-Class II tetramers. FVIII peptides spanning the exon 22-23 junction (encoding M2124-V2125) showed limited binding to MHCII proteins and low immunogenicity, with cytokine secretion from only one Int22Inv subject.

CONCLUSIONS

PBMCs from multiple subjects with an Int22Inv mutation, with and without a current FVIII inhibitor, responded to FVIII epitopes. Furthermore, the FVIII region encoded by the exon 22-23 junction sequence was not remarkably immunoreactive and is therefore unlikely to contain an immunodominant, promiscuous CD4 T-cell epitope. Our results indicate that putative intracellular expression of partial FVIII proteins does not confer T-cell tolerance to FVIII regions encoded by inverted mRNA or mRNA.

摘要

背景

近一半的重型血友病 A (HA) 是由内含子 22 倒位突变 (Int22Inv) 引起的,该突变会破坏包含 26 个外显子的基因。倒位的 mRNA 外显子 1-22 被转录,而包含外显子 23-26 的 mRNA 则从内含子 22 内的启动子转录。内含子 22 倒位的患者血浆中无法检测到 FVIII 活性或 FVIII 抗原 (交叉反应物质,CRM)。

目的

验证假设,即 (假定) 由倒位和 mRNA 编码的 FVIII 蛋白的细胞内合成赋予了对几乎整个 FVIII 序列的 T 细胞耐受,并评估由外显子 22-23 接头序列编码的区域的免疫原性。

患者/方法:通过 ELISPOT 检测来检测来自 30 名严重或中度 HA 患者(17 名存在 Int22Inv 突变)的外周血单核细胞 (PBMC) 对 FVIII 蛋白和肽的反应性细胞因子分泌,以检测免疫显性 T 细胞表位。还使用肽-MHCII 结合测定法来测试由外显子 22-23 接头区域编码的 FVIII 序列的潜在免疫原性。

结果

8 名 Int22Inv 患者的 PBMC 对 FVIII 蛋白和/或肽的刺激显示出强烈的细胞因子分泌,与 Conti-Fine 小组的早期出版物一致。肽 ELISPOT 检测鉴定了 FVIII 的免疫原性区域。通过用肽加载的 HLA-II 四聚体染色 Int22Inv CD4 T 细胞,证实了对 mRNA 外显子 1-22 和 mRNA 内编码序列的特异性。跨越外显子 22-23 接头 (编码 M2124-V2125) 的 FVIII 肽与 MHCII 蛋白结合有限,免疫原性低,只有一名 Int22Inv 患者的细胞因子分泌。

结论

具有和不具有当前 FVIII 抑制剂的 Int22Inv 突变的多个患者的 PBMC 对 FVIII 表位有反应。此外,由外显子 22-23 接头序列编码的 FVIII 区域没有明显的免疫反应性,因此不太可能包含免疫显性、混杂的 CD4 T 细胞表位。我们的结果表明,假定的部分 FVIII 蛋白的细胞内表达不会赋予对由倒位 mRNA 或 mRNA 编码的 FVIII 区域的 T 细胞耐受。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdcd/10015889/075293de6b5d/fimmu-14-1128641-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验